Where in Europe You Can Get Psychedelic Therapy (2026)

Ask where psychedelic therapy is legal in Europe and you get a map with four different layers that rarely line up: what is approved, what is reimbursed, what private clinics may offer, and what exists only inside research. This guide puts the layers side by side, substance by substance, for July 2026. Every claim here is drawn from our verified country and evidence guides, which are checked against the leading sector sources — the Magnetar Access × Blossom reimbursement report, Blossom's country pages and Psychedelic Alpha's legal tracker — plus the primary regulators.

One cross-border reality first. EU citizens do have a right to seek healthcare in other member states under Directive 2011/24/EU, with reimbursement from their home system (European Commission overview). In practice that right rarely helps here: home systems reimburse only treatments included in their own benefit basket, at their own rates, and often only with prior authorisation — so a treatment your country does not cover at home generally will not be covered abroad either. Plan on the assumption that reimbursement does not travel, and treat any exception as a bonus your insurer confirms in writing.

TL;DR Esketamine is the wide route: reimbursed in Germany, the Netherlands, Poland, Switzerland, Belgium, Italy, Ireland, Spain, Finland, Czechia, Portugal, Denmark and Scotland — while England and Wales are private-only, France is hospital-only with no private market, and Norway funds generic IV ketamine instead. Private ketamine clinics operate legally in the UK, Germany, Switzerland, Spain, Poland, Czechia and Sweden. Psilocybin outside trials means exactly three countries: Switzerland (limited medical use), Germany (two compassionate-use sites) and Czechia (framework live, rollout pending). MDMA therapy exists in Switzerland only. Cross-border reimbursement usually does not travel; trials are the one genuinely open cross-border door.

Esketamine (Spravato): the widest map

Esketamine nasal spray is licensed EU-wide for treatment-resistant depression, so the question is never legality — it is whether the public system pays, and under what criteria. The full criteria live in our reimbursement map; here is the 2026 picture at a glance:

Country	Public coverage in 2026	The one thing to know
Germany	Reimbursed (GKV)	≥2 failed antidepressants; office-based practices since 10/2023 — guide
Netherlands	Reimbursed (basic package, since 09/2021)	2 antidepressants + 1 augmentation failed; ENC-NL centers — guide
Poland	Fully funded (NFZ program B.147)	Ages 18–75, max 34 weeks; live waiting-time portal — guide
Switzerland	Reimbursed (OKP) since 10/2025	52 designated centers, insurer pre-approval, 10-month cap — guide
Belgium	Reimbursed since 06/2021	Hospital-administered; per-patient prior authorization
Italy	Hospital medicine (Classe H) since 05/2022	Regionally authorized centers; AIFA registry
Ireland	Reimbursed (HSE) since 01/2022	Psychiatrist-initiated
Spain	Hospital-financed since 11/2022	≥3 failed strategies incl. augmentation; strong regional variation — guide
Finland	Kela-reimbursed since 08/2023	Unique pharmacy-dispensing model; ≥3 failed treatments incl. psychotherapy
Czechia	Reimbursed since 02/2025	Under 65; exceptional approval possible beyond criteria — guide
Portugal	Hospital settings since 05/2025	Stricter national criteria
Denmark	Recommended by Medicinrådet 11/2025	≥3 failed antidepressants in current episode
UK — Scotland	Reimbursed (SMC, restricted)	NHS route via psychiatrist — guide
UK — England & Wales	Not reimbursed (NICE TA854)	Private clinics only — guide
France	Hospital-only	Under 65, narrow criteria; no private market — guide
Sweden	Formally possible, use "strongly restrained"	Region-by-region funding, in practice after ~4+ failed alternatives
Norway	Spravato rejected	Funds generic IV ketamine instead — see below
Austria	Not in the outpatient code	Inpatient via hospital financing; case-by-case approval

The pattern: if you live in continental Europe and can document two adequate failed antidepressant courses (three strategies in Spain, the Netherlands and Finland), a publicly funded esketamine route probably exists in your own country — which is almost always easier than crossing a border for it, because every one of these systems is wired to national insurance.

Ketamine: where private clinics legally operate

Off-label ketamine prescribing by a licensed physician is lawful across Europe, but an actual private clinic market only exists in some countries. Where it does, prices and regulators differ — our clinic-choice guide covers vetting in detail:

United Kingdom — the most developed private market, CQC-registered clinics, roughly £300–800 per infusion (UK guide);
Germany — private practices in most large cities, roughly €200–400 per infusion (Germany guide);
Switzerland — legal off-label infusions around CHF 300–500, self-pay (Switzerland guide);
Spain — private clinics in Barcelona, Madrid and Mallorca; full KAP programs run into the thousands (Spain guide);
Poland — private clinics in Warsaw, Wrocław and other large cities, self-pay (Poland guide);
Czechia — Prague's Psyon clinic offers ketamine-assisted psychotherapy with partial coverage from seven insurers — as far as we know, the only insurer-supported KAP in Europe (Czechia guide);
Sweden — private clinics exist (Stockholm around 4,500–5,000 SEK per session), with full courses at 20,000–30,000 SEK;
Norway — the outlier in the other direction: since August 2025 the public system funds generic IV ketamine for treatment-resistant depression in specialist services — a world-first decision, delivered publicly rather than through a clinic market;
France — effectively no private market: ketamine for depression is hospital-only, with a March 2026 compassionate framework for suicidal crisis (France guide).

Psilocybin: three narrow exceptions, trials everywhere else

Psilocybin is not an approved medicine anywhere in the EU. Outside clinical trials, lawful access exists in exactly three countries, none of them open-door:

Switzerland — the limited medical use program: individually authorized physicians treat named patients under Article 8 Narcotics Act permits, psilocybin since 2021. Around 100 physicians and 723 patients across the program in 2024, mostly self-paid, with waitlists of many months — and it is built for patients in Swiss care.
Germany — the EU's first compassionate use program, at exactly two sites (ZI Mannheim and OVID Berlin), for treatment-resistant depression only, roughly 50 patients in the first year. The drug is provided free by law; the initial BfArM listing runs to 11 July 2026, so current status should be confirmed with the sites.
Czechia — the first EU country with a full legal framework for medical psilocybin, in force since 1 January 2026. The honest status: treatment has not started, no waiting list exists, and NUDZ expects delivery to begin in the second half of 2026.

Everywhere else, psilocybin therapy means a clinical trial — and the research route is real: Compass Pathways' two Phase 3 trials in treatment-resistant depression met their primary endpoints in 2025 and 2026, and studies are recruiting across Europe (evidence review, trials guide). Anyone selling "psilocybin therapy" in any other European country today is operating outside the law, whatever the setting looks like.

MDMA: one country, plus research

MDMA-assisted therapy is legally available in exactly one European country: Switzerland, inside the same limited medical use program, where it has been used since 2014 — mostly for PTSD (Switzerland guide). It is not an approved medicine in the EU or anywhere else; the US FDA declined approval in August 2024 and asked for a further Phase 3 trial (evidence review).

Beyond Switzerland, the only lawful route is research, and in July 2026 it is thin: a PTSD study at ARQ Centrum'45 in the Netherlands is the notable recruiting European trial, while no MDMA trial is currently recruiting in Germany, Czechia, the UK or France. Registries change — check ClinicalTrials.gov and see the trials guide for how participation works.

What travelling for treatment actually means

Cross-border treatment sounds like one decisive trip. For this field, it almost never is — and being honest about the logistics prevents expensive mistakes.

These are repeated treatments, not procedures. Esketamine runs on recurring supervised sessions — more frequent at first, then tapering — across months, with a cap of 34 weeks in Poland and 10 months in Switzerland where those systems apply. Private ketamine courses typically mean around six sessions over two to four weeks, then maintenance decisions. Swiss program treatments involve preparation, long supervised dosing days and integration inside an ongoing psychotherapy. Multiply every session by travel and accommodation, and add the universal rule that you cannot drive after any dosing session.

The paying systems are national. Reimbursed routes run on domestic insurance: Polish NFZ centers, Dutch basic-package coverage, Czech insurers, Swiss OKP with residency-based care. The Swiss limited medical use program involves residency requirements and providers who insist on local follow-up, and the Czech psilocybin framework is being built for the Czech healthcare system — not for treatment tourism.

Aftercare happens at home. The weeks after treatment — integration, symptom measurement, medication management, relapse planning — need a clinician where you live. A realistic cross-border plan is arranged with your home psychiatrist before the first trip, not after the last one.

Who can realistically do it: patients near a border with a private-market country (self-pay ketamine in Germany or Spain, for instance, confirmed against our clinic checklist); patients enrolling in a clinical trial, which is free, legal and the one route genuinely designed to accept suitable candidates from further away — though screening is strict and travel is usually self-funded (trials guide). For everyone else, the strongest first move is usually the unglamorous one: document your treatment history and check what your own country already covers with our eligibility check.

Frequently asked questions

Can I use the EU cross-border care directive to get treatment abroad reimbursed?

Usually not for these treatments. The directive entitles you to reimbursement only for care your home system includes in its own basket, at home rates, frequently subject to prior authorisation (European Commission). If esketamine is closed to you at home, that closure follows you; if it is open at home, going abroad rarely makes sense. Ask your national contact point and get any promise in writing.

Which country is "easiest" for psychedelic therapy?

There is no single answer, because access is wired to residence and insurance. For a resident, Poland's fully funded program with its live waiting-time portal, Germany's office-based esketamine, and Czechia's combination of reimbursed Spravato and insurer-supported KAP are among the smoothest systems. For an outsider, none of them are easy — which is the honest headline of this page.

Can I travel to Switzerland for MDMA or psilocybin therapy?

Realistically, no. The limited medical use program authorizes named patients under individual physician permits, involves residency requirements, and providers require repeated in-person visits and local follow-up. Exceptions are rare, waitlists run many months, and anyone advertising fast access to the program is a red flag (Switzerland guide).

Is any country besides Switzerland offering legal MDMA therapy?

No. As of July 2026, MDMA-assisted therapy outside Switzerland exists only inside clinical trials, and few European MDMA trials are recruiting. Commercial MDMA "therapy" anywhere else in Europe is illegal.

What about psilocybin truffle retreats in the Netherlands?

They are legal as wellness businesses — psilocybin truffles are lawful to sell there — but they are not medical treatment: no licensing as healthcare, no medical screening obligations, no insurer coverage (Netherlands guide). They belong in a different category from everything else on this page.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Coverage, criteria and legal frameworks change quickly in this field; always verify current rules with the national regulator, your insurer and a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.

Where in Europe Can You Actually Get Psychedelic Therapy in 2026?